Expert Consensus Validates Clinical Potential of Circulating Tumor Cells, Highlights Parsortix Platform as Leading Technology
核心洞察
A major international expert consensus published in the European Journal of Cancer confirms the growing clinical relevance of circulating tumor cell (CTC) analysis in cancer management.
Ninety percent of 32 global oncologists and research leaders believe CTCs will become routine in clinical practice within five years, particularly for metastatic cancer treatment.
The consensus identifies CTCs as providing unique biological insights not captured by circulating tumor DNA (ctDNA) and positions them to transform cancer care through prognosis, treatment monitoring, and precision medicine.
A landmark international expert consensus has validated the clinical potential of circulating tumor cells (CTCs) in cancer management, with 90% of participating oncologists predicting their integration into routine clinical practice within five years. The study, published in the European Journal of Cancer, represents a significant milestone in overcoming historical clinical skepticism surrounding CTC technology.
Expert Panel Endorses CTC Clinical Integration
The consensus involved 32 global oncologists and research leaders who agreed that CTCs provide unique biological insights not captured by circulating tumor DNA (ctDNA). The experts emphasized that CTCs are poised to transform cancer care through their applications in prognosis, treatment monitoring, and characterization to inform precision medicine approaches.
The publication provides comprehensive guidance for clinical use of CTCs across cancer types and strongly supports their implementation in metastatic cancer treatment. According to the consensus, this represents the removal of the biggest historical barrier to CTC adoption - clinical skepticism among healthcare professionals.
Parsortix Platform Emerges as Leading Technology
Among the technologies evaluated, 40% of the expert panel identified CelLBxHealth (搜索)'s Parsortix platform as the most promising next-generation technology for clinical applications. The platform's patent-protected technology harvests CTCs from blood and can be seamlessly integrated with existing laboratory instruments for comprehensive downstream analysis, including whole-cell imaging, proteomic profiling, and full genomic workflows.
Peter Collins, Chief Executive Officer of CelLBxHealth (搜索), stated: "This independent expert consensus further demonstrates the important role that CTCs stand to play in cancer treatment into the future, and identifies the Parsortix platform as a go-to platform in the space. In this context, CelLBxHealth is uniquely positioned as the next generation standard to enable clinicians and researchers to harness the full diagnostic and therapeutic potential of CTCs."
Distinct Advantages Over ctDNA
The consensus highlighted that CTCs provide distinct and impactful information that is not captured by circulating tumor DNA analysis. This differentiation positions CTC technology as a complementary rather than competing approach to existing liquid biopsy methods, potentially expanding the diagnostic toolkit available to oncologists.
Company Positioning and Future Outlook
CelLBxHealth (搜索) operates as a global precision CTC intelligence company, with commercial activities centered on product sales through CRO and clinical lab partnerships, lab developed tests through strategic partnerships, and laboratory services including clinical trial support. The company delivers services from its GCLP certified UK laboratory.
The company has announced plans to raise approximately £6 million through a combination of retail investor offerings and institutional placing, with an expected announcement by early December. CelLBxHealth (搜索) currently maintains a cash runway into early 2026 and has commenced discussions with shareholders regarding the fundraising initiative.